Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + BUCY2 Conditioning for MDS
NCT06279338Not yet recruiting
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS). Primary endpoint: Progression-Free Survival at 18 months. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06279338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279338.